Abstract
Malignant pleural mesothelioma (MPM) is an uncommon but aggressive neoplasm with low survival rates. For patients with early stage resectable MPM the role of radical surgery remains controversial and multimodal treatment might improve patient prognosis. Dendritic cell therapy (DCT) with Mesopher proved to be safe and yielded promising results in patients with MPM, with single agent radiological activity, representing the rationale for a combined (neo)adjuvant approach with extended pleurectomy/decortication (eP/D) surgery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have